Display of Peptides on the Surface of Tobacco Mosaic Virus Particles
In this review, we focus on the potential that tobacco mosaic virus (TMV) has as a carrier for immunogenic epitopes, and the factors that must be considered in order to bring products based on this platform to the market. Large Scale Biology Corporation developed facile and scaleable methods for manufacture of candidate peptide display vaccines based on TMV. We describe how rational design of peptide vaccines can improve the manufacturability of particular TMV products. We also discuss downstream processing and purification of the vaccine products, with particular attention to the metrics that a product must attain in order to meet criteria for regulatory approval as injectable biologics.
Keywordstobacco mosaic virus vaccine plant virus-like particle papillomavirus
Unable to display preview. Download preview PDF.
- Birkett A, Lyons K, Schmidt A, et al (2002) A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 70:6860–6870PubMedCrossRefGoogle Scholar
- Fitzmaurice WP (2002) U.S. Patent No. 6344597Google Scholar
- Garger SJ, Holtz RB, et al (2000) U.S. patent No. 6033895Google Scholar
- Garger SJ, Holtz RB, et al (2001) U.S. patent No. 6303779Google Scholar
- Pogue GP, Lindbo JA, McCulloch MJ, et al (2004) U.S. patent No. 6730306 B1Google Scholar
- Timian RG, Savage SM (1966) Purification of barley stripe mosaic virus with chloroform and charcoal. Phytopathology 56:1233–1235Google Scholar